NasdaqCM:BLTEPharmaceuticals
Belite Bio (BLTE): Assessing Valuation After Sharp Drop in Quarterly Losses
Belite Bio (NasdaqCM:BLTE) just delivered its second-quarter earnings, and while the company is still in the red, something has changed: the loss is shrinking. For the quarter ended June, the net loss came in at $9.49 million compared to $16.32 million a year ago, and losses per share followed suit. Investors have been watching closely for any sign the biotech’s cash burn is easing, and this result might attract some attention. It is not common to see such a significant improvement,...